These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37446121)

  • 1. Site-Specific RNA Editing of Stop Mutations in the CFTR mRNA of Human Bronchial Cultured Cells.
    Chiavetta RF; Titoli S; Barra V; Cancemi P; Melfi R; Di Leonardo A
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating REPAIRv2 as a Tool to Edit
    Melfi R; Cancemi P; Chiavetta R; Barra V; Lentini L; Di Leonardo A
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.
    Mention K; Cavusoglu-Doran K; Joynt AT; Santos L; Sanz D; Eastman AC; Merlo C; Langfelder-Schwind E; Scallan MF; Farinha CM; Cutting GR; Sharma N; Harrison PT
    Hum Mol Genet; 2023 Nov; 32(23):3237-3248. PubMed ID: 37649273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
    Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
    J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
    Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
    Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
    [No Abstract]   [Full Text] [Related]  

  • 8. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.
    Bedwell DM; Kaenjak A; Benos DJ; Bebok Z; Bubien JK; Hong J; Tousson A; Clancy JP; Sorscher EJ
    Nat Med; 1997 Nov; 3(11):1280-4. PubMed ID: 9359706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
    Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
    Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.
    McHugh DR; Steele MS; Valerio DM; Miron A; Mann RJ; LePage DF; Conlon RA; Cotton CU; Drumm ML; Hodges CA
    PLoS One; 2018; 13(6):e0199573. PubMed ID: 29924856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.
    Li C; Liu Z; Anderson J; Liu Z; Tang L; Li Y; Peng N; Chen J; Liu X; Fu L; Townes TM; Rowe SM; Bedwell DM; Guimbellot J; Zhao R
    PLoS One; 2023; 18(11):e0295009. PubMed ID: 38019847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of W1282X CFTR activity by enhanced expression.
    Rowe SM; Varga K; Rab A; Bebok Z; Byram K; Li Y; Sorscher EJ; Clancy JP
    Am J Respir Cell Mol Biol; 2007 Sep; 37(3):347-56. PubMed ID: 17541014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.
    Xue X; Mutyam V; Thakerar A; Mobley J; Bridges RJ; Rowe SM; Keeling KM; Bedwell DM
    Hum Mol Genet; 2017 Aug; 26(16):3116-3129. PubMed ID: 28575328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
    Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I
    Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.
    Du M; Jones JR; Lanier J; Keeling KM; Lindsey JR; Tousson A; Bebök Z; Whitsett JA; Dey CR; Colledge WH; Evans MJ; Sorscher EJ; Bedwell DM
    J Mol Med (Berl); 2002 Sep; 80(9):595-604. PubMed ID: 12226741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.
    Laselva O; Eckford PD; Bartlett C; Ouyang H; Gunawardena TN; Gonska T; Moraes TJ; Bear CE
    J Cyst Fibros; 2020 Sep; 19(5):717-727. PubMed ID: 31831337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations.
    Premchandar A; Ming R; Baiad A; Da Fonte DF; Xu H; Faubert D; Veit G; Lukacs GL
    Front Pharmacol; 2024; 15():1389586. PubMed ID: 38725656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.